Table of ContentsView AllTable of ContentsParkinson’s DiseaseHow CommonBy EthnicityBy Age and GenderCausesMortalityEarly DetectionNext in Parkinson’s Disease GuideWhat Is Parkinson’s Disease?
Table of ContentsView All
View All
Table of Contents
Parkinson’s Disease
How Common
By Ethnicity
By Age and Gender
Causes
Mortality
Early Detection
Next in Parkinson’s Disease Guide
Each year, about 60,000 people are diagnosed with Parkinson’s disease (PD) in the United States. Worldwide, more than 10 million people are living with PD.It’s one of the most common neurodegenerative diseases, and about 4% of people with PD are diagnosed before 50.
FG Trade / Getty Images
Parkinson’s Disease Overview
Parkinson’s disease causes problems with movement, and it also causes non-motor symptoms, usually in the later stages of the disease.
The most common characteristics of Parkinson’s disease:
Symptoms of Parkinson’s Disease
How Common Is Parkinson’s Disease?
The incidence of Parkinson’s disease has been increasing in most countries around the world. This is likely due to an increase in life expectancy in the general population, as the condition is seen more often with older age.In the United States, Parkinson’s disease affects almost six per 1,000 people age 45 and over.
Parkinson’s disease affects people of all races and geographic regions worldwide. The incidence is higher among White Americans than among Black and Asian Americans. It is higher among Hispanics than among White Americans.
It is not known whether the different incidence and prevalence rates among people of different ethnic backgrounds are due to environmental or genetic factors.
Parkinson’s disease generally affects people who are over 60 years old. Early-onset Parkinson’s disease is defined as beginning before age 50. The prevalence of Parkinson’s disease increases with increasing age, and it is estimated to affect 1 in 40 people who are 85 to 89 years old.
People who begin to have symptoms at an older age generally have more severe symptoms and also have more comorbid conditions (other health issues occurring at the same time), such as heart disease, lung disease, or diabetes.
Parkinson’s disease is more common among males than females, affecting approximately twice as many males.
Causes of Parkinson’s Disease and Risk Factors
The underlying cause or trigger for these changes is not known, although some people have a family history of the condition.The mechanism is known for some of the familial types.
Many potential risk factors have been examined as possible triggers, including exposure to chemicals, but no environmental or lifestyle factors have been confirmed as causing Parkinson’s disease.
What Is Parkinson’s Disease?
What Are the Mortality Rates for Parkinson’s Disease?
Parkinson’s disease is not fatal, but it is often a handicap in advanced stages. Some people have a higher risk of death associated with Parkinson’s disease, but this is not the case for everyone. Many people who have the condition have a normal life expectancy.
People with advanced Parkinson’s disease may develop a type of cognitive impairment known asParkinson’s dementia. Additionally, people who have Parkinson’s disease can develop other types of dementia, includingAlzheimer’s disease. Cognitive impairment is a risk factor for death in Parkinson’s disease.
People who have an age of onset before age 40 have a more than fivefold higher risk of death (from any cause) compared to people of the same age in the general population.
Screening and Early Detection
There is no specific test that can tell in advance whether someone will one day develop Parkinson’s disease. Most of the time, people who develop the condition did not have any early signs in the years before the disease started to cause symptoms. Many people with Parkinson’s disease had a physically active lifestyle before the disease started to have any effects.
Parkinson’s disease is diagnosed based on a physical examination, which includes a comprehensiveneurological examination. Sometimesbrain imagingor other tests are ordered to see whether another brain condition, such as a stroke, brain injury, or a tumor, could be causing the symptoms.
There is no definitive laboratory test or other test to confirm a diagnosis of Parkinson’s disease.
Summary
Parkinson’s disease is a progressive neurological condition that begins in late adulthood, generally after age 65. It has been increasing in prevalence worldwide. This is likely due to rising life expectancy rate throughout the world. The condition affects men more often than women and White Americans more often than Black Americans.
The biological cause of Parkinson’s disease is associated with a decrease in dopamine activity in the brain and degeneration of specific areas of the brain, but a specific trigger for these problems is unknown.
There’s no confirmatory test for Parkinson’s disease. The diagnosis is made based on certain movements and physical features that are detected with a medical physical examination.
Parkinson’s disease has a substantial effect on a person’s quality of life. It doesn’t always cause a decreased life expectancy, but it can cause a shortened life span for people who develop dementia.
Frequently Asked Questions
Generally, treatment with medications that provide more dopamine or imitate the action of dopamine helps improve the symptoms for a few hours at a time. These treatments are more effective early in the disease course. As the disease progresses, a higher dose is often needed to achieve the same effect, and medication side effects worsen.Learn MoreTreatment Options for Parkinson’s
Generally, treatment with medications that provide more dopamine or imitate the action of dopamine helps improve the symptoms for a few hours at a time. These treatments are more effective early in the disease course. As the disease progresses, a higher dose is often needed to achieve the same effect, and medication side effects worsen.
Learn MoreTreatment Options for Parkinson’s
Learn MoreWhat Is Parkinsonism?
Because they are both well-known neurological diseases, many people may confuse amyotrophic lateral sclerosis (ALS) with Parkinson’s disease. However, the two conditions are not similar.ALS causes gradually worsening paralysis of the muscles, and it is fatal within a few years after diagnosis. People who have Parkinson’s disease are not paralyzed and usually survive for many years with the disease.Learn MoreWhat Is ALS?
Because they are both well-known neurological diseases, many people may confuse amyotrophic lateral sclerosis (ALS) with Parkinson’s disease. However, the two conditions are not similar.ALS causes gradually worsening paralysis of the muscles, and it is fatal within a few years after diagnosis. People who have Parkinson’s disease are not paralyzed and usually survive for many years with the disease.
Because they are both well-known neurological diseases, many people may confuse amyotrophic lateral sclerosis (ALS) with Parkinson’s disease. However, the two conditions are not similar.
ALS causes gradually worsening paralysis of the muscles, and it is fatal within a few years after diagnosis. People who have Parkinson’s disease are not paralyzed and usually survive for many years with the disease.
Learn MoreWhat Is ALS?
8 SourcesVerywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.Marras C, Beck JC, Bower JH, et al.Prevalence of Parkinson’s disease across North America.npj Parkinson’s Disease. 2018;4(1):21. doi:10.1038/s41531-018-0058-0Parkinson’s Foundation.Who has Parkinson’s?MedlinePlus.Parkinson disease.Ou Z, Pan J, Tang S, Duan D, Yu D, Nong H, Wang Z.Global trends in the incidence, prevalence, and years lived with disability of Parkinson’s disease in 204 countries/territories from 1990 to 2019.Front Public Health.2021;9:776847. doi:10.3389/fpubh.2021.776847Marras C, Beck JC, Bower JH, et al.Prevalence of Parkinson’s disease across North America.NPJ Parkinsons Dis. 2018;4:21. doi:10.1038/s41531-018-0058-0Wright Willis A, Evanoff BA, Lian M, Criswell SR, Racette BA.Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries.Neuroepidemiology. 2010;34(3):143-51. doi:10.1159/000275491Pagano G, Ferrara N, Brooks DJ, Pavese N.Age at onset and Parkinson disease phenotype.Neurology.2016;86(15):1400-1407. doi:10.1212/WNL.0000000000002461Hustad E, Myklebust TÅ, Gulati S, Aasly JO.Increased mortality in young-onset Parkinson’s disease.J Mov Disord. 2021;14(3):214-220. doi:10.14802/jmd.21029
8 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.Marras C, Beck JC, Bower JH, et al.Prevalence of Parkinson’s disease across North America.npj Parkinson’s Disease. 2018;4(1):21. doi:10.1038/s41531-018-0058-0Parkinson’s Foundation.Who has Parkinson’s?MedlinePlus.Parkinson disease.Ou Z, Pan J, Tang S, Duan D, Yu D, Nong H, Wang Z.Global trends in the incidence, prevalence, and years lived with disability of Parkinson’s disease in 204 countries/territories from 1990 to 2019.Front Public Health.2021;9:776847. doi:10.3389/fpubh.2021.776847Marras C, Beck JC, Bower JH, et al.Prevalence of Parkinson’s disease across North America.NPJ Parkinsons Dis. 2018;4:21. doi:10.1038/s41531-018-0058-0Wright Willis A, Evanoff BA, Lian M, Criswell SR, Racette BA.Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries.Neuroepidemiology. 2010;34(3):143-51. doi:10.1159/000275491Pagano G, Ferrara N, Brooks DJ, Pavese N.Age at onset and Parkinson disease phenotype.Neurology.2016;86(15):1400-1407. doi:10.1212/WNL.0000000000002461Hustad E, Myklebust TÅ, Gulati S, Aasly JO.Increased mortality in young-onset Parkinson’s disease.J Mov Disord. 2021;14(3):214-220. doi:10.14802/jmd.21029
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
Marras C, Beck JC, Bower JH, et al.Prevalence of Parkinson’s disease across North America.npj Parkinson’s Disease. 2018;4(1):21. doi:10.1038/s41531-018-0058-0Parkinson’s Foundation.Who has Parkinson’s?MedlinePlus.Parkinson disease.Ou Z, Pan J, Tang S, Duan D, Yu D, Nong H, Wang Z.Global trends in the incidence, prevalence, and years lived with disability of Parkinson’s disease in 204 countries/territories from 1990 to 2019.Front Public Health.2021;9:776847. doi:10.3389/fpubh.2021.776847Marras C, Beck JC, Bower JH, et al.Prevalence of Parkinson’s disease across North America.NPJ Parkinsons Dis. 2018;4:21. doi:10.1038/s41531-018-0058-0Wright Willis A, Evanoff BA, Lian M, Criswell SR, Racette BA.Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries.Neuroepidemiology. 2010;34(3):143-51. doi:10.1159/000275491Pagano G, Ferrara N, Brooks DJ, Pavese N.Age at onset and Parkinson disease phenotype.Neurology.2016;86(15):1400-1407. doi:10.1212/WNL.0000000000002461Hustad E, Myklebust TÅ, Gulati S, Aasly JO.Increased mortality in young-onset Parkinson’s disease.J Mov Disord. 2021;14(3):214-220. doi:10.14802/jmd.21029
Marras C, Beck JC, Bower JH, et al.Prevalence of Parkinson’s disease across North America.npj Parkinson’s Disease. 2018;4(1):21. doi:10.1038/s41531-018-0058-0
Parkinson’s Foundation.Who has Parkinson’s?
MedlinePlus.Parkinson disease.
Ou Z, Pan J, Tang S, Duan D, Yu D, Nong H, Wang Z.Global trends in the incidence, prevalence, and years lived with disability of Parkinson’s disease in 204 countries/territories from 1990 to 2019.Front Public Health.2021;9:776847. doi:10.3389/fpubh.2021.776847
Marras C, Beck JC, Bower JH, et al.Prevalence of Parkinson’s disease across North America.NPJ Parkinsons Dis. 2018;4:21. doi:10.1038/s41531-018-0058-0
Wright Willis A, Evanoff BA, Lian M, Criswell SR, Racette BA.Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries.Neuroepidemiology. 2010;34(3):143-51. doi:10.1159/000275491
Pagano G, Ferrara N, Brooks DJ, Pavese N.Age at onset and Parkinson disease phenotype.Neurology.2016;86(15):1400-1407. doi:10.1212/WNL.0000000000002461
Hustad E, Myklebust TÅ, Gulati S, Aasly JO.Increased mortality in young-onset Parkinson’s disease.J Mov Disord. 2021;14(3):214-220. doi:10.14802/jmd.21029
Meet Our Medical Expert Board
Share Feedback
Was this page helpful?Thanks for your feedback!What is your feedback?OtherHelpfulReport an ErrorSubmit
Was this page helpful?
Thanks for your feedback!
What is your feedback?OtherHelpfulReport an ErrorSubmit
What is your feedback?
